Med-X, Inc. Secures $ 100 Million Expansion Capital Commitment to Global Emerging Markets (GEM)

LOS ANGELES, August 6, 2021 / PRNewswire / – Today, Med-X, Inc. (MED-X) announced a $ 100 million the capital commitment of GEM Global Yield, LLC SCS (GGY), a Luxembourgprivate alternative investment group. Under the agreement, GGY will provide MED-X with a share subscription facility of up to $ 100 million for a period of 36 months following the IPO of the ordinary shares of MED-X.

Med-X will control the timing and maximum number of drawdowns and, under this agreement, may issue a drawdown notice for up to $ 10 million in shares on the first day of trading. Along with a public listing, Med-X will issue warrants to GEM to purchase up to 4.0% of the company’s common stock. Flagship division of Med-X, Nature-Cide, has developed a range of all-natural professional pest control applications. One of its pest control solutions for vector control is continuously tested by third parties with amazing results recorded. The products are intended to be expanded, through major distribution partners in various regions of the world.

“Investing in GEM shares strengthens our business model as well as our long-term financial goals while strengthening and continuing our mission on the global stage,” says Founder and Chief Operating Officer Matthew Mills. “So far we have been very successful in taking out our own Regulation A + Offer, which has generated investments of more than 3,600 people over the past 4 years. This new capital commitment of $ 100 million should allow the Company to move forward in its M&A strategy, while propelling the brands in a way where our mission of “Make a difference every day” will take it to a whole new level, ”says Mills.

About Med-X, Inc.

Med-X, Inc. is a Nevada company incorporated in February 2014 support the rapidly evolving sectors of green and environmentally friendly products and services with its Nature-Cide, Thermal-Help and Malibu brands divisions as well as the emerging hemp and cannabis industry through activities such as compound identification and extraction of cannabidiol (CBD) compounds identified for the current demand of the medical industry.
For more information about Med-X, Inc., please visit, email [email protected] or call 818-349-2870

About GEM Global Yield, LLC SCS Group

About GEM
Global Emerging Markets (“GEM”) is a $ 3.4 billion, an alternative investment group with offices in Paris, new York and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed more than 440 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return and liquidity profile. The family of funds and investment vehicles provides GEM and its partners with exposure to: buyouts of small and mid-cap companies, private investments in public equities and selected venture capital investments. For more information:

GEM contact:

Jean-Luc Bonnefoy: [email protected]

Contact Med-X

Matthew Mills: [email protected]

The securities offered by Med-X, Inc. are highly speculative. Invest in shares of MED-X, INC. carries a significant risk. This investment is only suitable for people who can afford to lose their entire investment. Additionally, investors should understand that an investment can be illiquid for an indefinite period. No public market currently exists for the securities and if and when a public market develops as a result of this offering, it may not continue. You should read the Regulation A + Offer Circular Deposits with the Securities Exchange Commission before making any investment in the Company.
This article may contain forward-looking statements regarding projected business performance, results of operations, financial condition and other aspects of the company, expressed by words such as “expected”, “anticipated”, “projected” and ” foreseen “. Please note that these statements are estimates only and that there is no guarantee that the results stated or implied by the forward-looking statements will actually be achieved by the company. Forward-looking statements may be based on management’s assumptions which prove to be incorrect. The company and its activities are subject to substantial risks and potential events beyond its control which would cause material differences between expected and actual results, including the company suffering operating losses and suffering material adverse events. unexpected.



View original content to download multimedia:

SOURCE Med-X, Inc.

Source link

Previous Acadia Pharmaceuticals Inc (ACAD) Q2 2021 Earnings Call Transcript
Next Man Group PLC : Form 8.3